Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis

Afatinib, a second-generation, irreversible pan-HER inhibitor, shows better suppression of T790M-positive lung cancer cells than gefitinib in preclinical studies. However, whether the effect of afatinib on T790M acquisition differs from that of gefitinib when used clinically as first-line therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Byung Woo, Kim, Jae Hoon, Lee, Seung Hyeon, Choi, Chang-Min, Rho, Jin Kyung, Yoon, Shinkyo, Lee, Dae Ho, Kim, Sang-We, Jang, Tae-Won, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484288/
https://www.ncbi.nlm.nih.gov/pubmed/31030101
http://dx.doi.org/10.1016/j.tranon.2019.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484288/
https://www.ncbi.nlm.nih.gov/pubmed/31030101
http://dx.doi.org/10.1016/j.tranon.2019.04.004

Ejemplares similares